Curis Lifesciences IPO Subscription Day 2: Check Online

Check Expert’s Verdicts on Curis Lifesciences IPO. 

Here is the Curis Lifesciences IPO launched on 7th November 2025. Bidding for the issue will close on 11th November 2025. The primary aim of the Curis Lifesciences IPO is to raise ₹27.52 crores from the market. Additionally, the Curis Lifesciences IPO has received an impressive level of subscription, indicating that the shares will likely be listed at a premium. Scroll down to check the Curis Lifesciences IPO subscription and details. 

Curis Lifesciences IPO Details 

The price band for the Curis Lifesciences IPO has been prescribed at ₹120 to ₹128 per share, with a total of 21,50,000 shares issued. Let’s segregate the share quota fixed for different categories of investors. 

Curis Lifesciences IPO Subscription Status

As of now, the Curis Lifesciences IPO has been subscribed to 3.75 times. Of these, 2.06 times are subscribed by retail investors, 1.58 times by non-institutional investors, and 8.34times by QII (Qualified Institutional Investors).  

The healthy subscription status indicates that investors are expecting higher returns at the time of the Curis Lifesciences IPO, scheduled for listing on 14th November 2025. Curis Lifesciences’ IPO also has a positive outlook, with the fresh issue of 22.00.000 shares to raise around Rs 27.52 crores.

Curis Lifesciences IPO GMP Today

We know that higher subscription levels drive grey-market premiums for IPOs. Let’s explore the Curis Lifesciences IPO GMP for 10th November 2025. 

The grey market premium for this IPO is 6.25% or Rs 8 per share. It indicates that the estimated listing price per share is Rs 136. Numerous factors played a pivotal role in the jump in Curis Lifesciences IPO GMP. These include higher subscription rates, favourable market sentiment, and investors’ positive attitude towards IPOs. 

About Curis Lifesciences IPO Ltd.

Curis Lifesciences Limited was established in 2010 and is a prominent pharmaceutical company that engages in the development, manufacturing, and distribution of various products. It has manufacturing units globally and domestically, through licenses and on a contract basis, and it markets its own brand. 

• Experienced Promoters and Management Team
• Wide range of Products
• Strategic Location of Manufacturing Facility
• Scalable Business Model
• Quality assurance

Curis Lifesciences Limited Financials

The company’s financial analysis is essential before applying for Curis Lifesciences Limited’s IPO. Look at the table to learn about Curis Lifesciences Limited’s financials. 

Explanation

Curis Lifesciences Limited’s revenue increased by 38% from ₹4.87 crore in March 2024 to ₹ 6.49 crore in March 2025. Moreover, the company’s PAT increased by 25% from ₹4.87 crores to ₹6.11  crores. Investors can analyse other relevant factors and make a decision accordingly.

Technical Indicators

Several technical indicators are available to assess a company’s potential to deliver returns. Use the parameters mentioned below to analyse the technical aspects of the Curis Lifesciences IPO.

Curis Lifesciences IPO Listing Expectations

Curis Lifesciences IPO Highlights: IPO allotment is still pending, as the bid closes today. However, given the current GMP or market sentiment, it is reasonable to expect higher listing gains for the share. A 6.25% jump in the GMP of Curis Lifesciences’ IPO suggests that the estimated listing price per share will be around Rs 136.

It will provide higher listing gains to investors who applied for this IPO. Also, the financial fundamentals of this business made it the experts’ top long-term recommendation. 

Curis Lifesciences IPO Dates

Note: IPO GMP is volatile, driven by market sentiment. Hence, one should conduct their research before investing in it.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Max Healthcare Q1 Results FY26: Q1 PAT Rises 30.35% to ₹307.97 Crore; Revenue Up 31.41% YoY

Minda Corporation Q1 Results FY26: Q1 PAT Rises 1.73% to ₹65.31 Crore; Revenue Up 16.23% YoY

Bharat Dynamics Q1 Results FY26: Q1 PAT Rises 154.30% to ₹18.35 Crore; Revenue Up 29.69% YoY

Elitecon International Q1 Results FY26: Q1 PAT Rises 349.99% to ₹20.41 Crore; Revenue Up 301.98% YoY

Elgi Equipments Q1 Results FY26: Q1 PAT Rises 17.58% to ₹85.60 Crore; Revenue Up 8.19% YoY

Aavas Financier Q1 Results FY26: Q1 PAT Rises 10.41% to ₹139.23 Crore; Revenue Up 15.70% YoY

Curis Lifesciences IPO IPO GMP: Day 2 IPO Live Updates